Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Identifieur interne : 001B47 ( Pmc/Curation ); précédent : 001B46; suivant : 001B48Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Auteurs : R. D. Rubens ; S. B. Kaye ; M. Soukop ; C. J. Williams ; M. H. Brampton ; A. L. HarrisSource :
- British Journal of Cancer [ 0007-0920 ] ; 1991.
Abstract
Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.
Url:
PubMed: 1764386
PubMed Central: 1977835
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B48
Links to Exploration step
PMC:1977835Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.</title>
<author><name sortKey="Rubens, R D" sort="Rubens, R D" uniqKey="Rubens R" first="R. D." last="Rubens">R. D. Rubens</name>
</author>
<author><name sortKey="Kaye, S B" sort="Kaye, S B" uniqKey="Kaye S" first="S. B." last="Kaye">S. B. Kaye</name>
</author>
<author><name sortKey="Soukop, M" sort="Soukop, M" uniqKey="Soukop M" first="M." last="Soukop">M. Soukop</name>
</author>
<author><name sortKey="Williams, C J" sort="Williams, C J" uniqKey="Williams C" first="C. J." last="Williams">C. J. Williams</name>
</author>
<author><name sortKey="Brampton, M H" sort="Brampton, M H" uniqKey="Brampton M" first="M. H." last="Brampton">M. H. Brampton</name>
</author>
<author><name sortKey="Harris, A L" sort="Harris, A L" uniqKey="Harris A" first="A. L." last="Harris">A. L. Harris</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">1764386</idno>
<idno type="pmc">1977835</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977835</idno>
<idno type="RBID">PMC:1977835</idno>
<date when="1991">1991</date>
<idno type="wicri:Area/Pmc/Corpus">001B48</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001B48</idno>
<idno type="wicri:Area/Pmc/Curation">001B47</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001B47</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.</title>
<author><name sortKey="Rubens, R D" sort="Rubens, R D" uniqKey="Rubens R" first="R. D." last="Rubens">R. D. Rubens</name>
</author>
<author><name sortKey="Kaye, S B" sort="Kaye, S B" uniqKey="Kaye S" first="S. B." last="Kaye">S. B. Kaye</name>
</author>
<author><name sortKey="Soukop, M" sort="Soukop, M" uniqKey="Soukop M" first="M." last="Soukop">M. Soukop</name>
</author>
<author><name sortKey="Williams, C J" sort="Williams, C J" uniqKey="Williams C" first="C. J." last="Williams">C. J. Williams</name>
</author>
<author><name sortKey="Brampton, M H" sort="Brampton, M H" uniqKey="Brampton M" first="M. H." last="Brampton">M. H. Brampton</name>
</author>
<author><name sortKey="Harris, A L" sort="Harris, A L" uniqKey="Harris A" first="A. L." last="Harris">A. L. Harris</name>
</author>
</analytic>
<series><title level="j">British Journal of Cancer</title>
<idno type="ISSN">0007-0920</idno>
<idno type="eISSN">1532-1827</idno>
<imprint><date when="1991">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
<journal-title>British Journal of Cancer</journal-title>
<issn pub-type="ppub">0007-0920</issn>
<issn pub-type="epub">1532-1827</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">1764386</article-id>
<article-id pub-id-type="pmc">1977835</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Rubens</surname>
<given-names>R. D.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Kaye</surname>
<given-names>S. B.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Soukop</surname>
<given-names>M.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Williams</surname>
<given-names>C. J.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Brampton</surname>
<given-names>M. H.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Harris</surname>
<given-names>A. L.</given-names>
</name>
</contrib>
</contrib-group>
<aff>ICRF Department of Clinical Oncology, UMDS, Guy's Hospital, London.</aff>
<pub-date pub-type="ppub"><month>12</month>
<year>1991</year>
</pub-date>
<volume>64</volume>
<issue>6</issue>
<fpage>1187</fpage>
<lpage>1188</lpage>
<abstract><p>Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001B47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:1977835 |texte= Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:1764386" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |